Pulmonary Sarcoidosis
27
4
5
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.4%
2 terminated out of 27 trials
86.7%
+0.2% vs benchmark
19%
5 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Role of Genetic Factors in the Development of Lung Disease
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
Comparison of Different Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
CASPA: CArdiac Sarcoidosis in PApworth
The Effect of Inspiratory Muscle Training and Breathing Exercises Combined With Upper Extremity and Trunk in Patients With Sarcoidosis
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
Study of Nicotine Patches in Patients With Sarcoidosis
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
Mycophenolate for Pulmonary Sarcoidosis